Prestige Consumer Healthcare (NYSE:PBH) Releases Earnings Results, Beats Estimates By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) posted its earnings results on Thursday. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded up $0.29 on Monday, reaching $87.29. 397,000 shares of the company traded hands, compared to its average volume of 318,635. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. The firm has a market capitalization of $4.31 billion, a PE ratio of 20.44, a PEG ratio of 2.43 and a beta of 0.50. The company has a 50 day moving average of $79.23 and a 200 day moving average of $75.51. Prestige Consumer Healthcare has a 52 week low of $62.35 and a 52 week high of $88.36.

Analyst Upgrades and Downgrades

PBH has been the subject of several analyst reports. DA Davidson increased their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday. Finally, Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.50.

Insider Activity at Prestige Consumer Healthcare

In other news, insider William P'pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.